Webinar: Discover Radiotheranostics in Nuclear Medicine

15 to 16 September 2022

← Back to events

Format: Online
Open to: CIVIS students & academics
Date: 15 to 16 September 2022

Discover the domain of radiotheranostics in nuclear oncology that is already implemented in clinical routine, and deepen your knowledge of the research and development of these new therapies.

This webinar aims to offer insights and instruction on current radiotheranostics in nuclear medicine and especially in oncology, that are already implemented in clinical routine. The event will allow participants to hear from high-level experts from CIVIS partner universities about the main aspects of radiotheranostics. It will offer an excellent opportunity for contacts and exchanges between students, academics, clinicians, and researchers from CIVIS universities.

Main topics addressed

Session 1. Radiopharmaceuticals for targeted radionuclide therapy
Session 2. Radiobiology
Session 3. Medical physics dosimetry in nuclear medicine
Session 4. Radiotheranostic in clinics
Session 5. Example of radioembolization
Session 6. Bottleneck and pending questions

Learning outcomes

Understanding the concept of radiotheranostics, their mechanism of action, the principles of radiobiology applied to radiotheranostics, the principles of dosimetry with practical examples, and knowing the major clinical applications that have demonstrated their effectiveness and safety in landmark clinical trials
Contact and exchange opportunities with academics/clinicians/researchers from CIVIS universities
Contact opportunity with students from CIVIS universities

Erwin Woff (Université libre de Bruxelles) – Erwin Woff is a full professor in Nuclear Medicine at the Faculty of Medicine of Université libre de Bruxelles (ULB) and clinical deputy of Nuclear Medicine Department at Institut Jules Bordet, Brussels, Belgium. He completed his medical training in 2009 and specialty in Nuclear Medicine at the Faculty of Medicine of ULB in 2014. He achieved his PhD at ULB in 2020 focused on the development and validation of prognostic and predictive imaging biomarkers by ¹⁸F-FDG-PET/CT. He is currently working on Artificial Intelligence in the field of Molecular Imaging in the framework of a post-doctorate involving active European collaboration between two prestigious oncologic centers by working half-time at the Institut Jules Bordet and half-time at the LITO (Laboratoire d’Imagerie Translationnelle en Oncologie, U1288) of the Institut Curie in Paris. He is the author and co-author of many peer-review publications in high-ranked journals. He has made multiple oral and poster presentations at international conferences. He is an active member of the European Association of Nuclear Medicine (EANM), the Belgian Society of Nuclear Medicine (BELNUC), and the Lymphoma Study Association (LYSA).
Benjamin Guillet (Aix-Marseille Université) - Benjamin Guillet is a full Professor in Pharmacology and Physiology at the faculty of pharmacy (Aix-Marseille Université), professor of “Institut national des sciences et techniques nucléaires” and head of Radiopharmacy department of Marseille University Hospital. B Guillet is also the Director of the European Imaging research center (CERIMED). Permanent Expert at French medicine agency and member of EANM radiopharmaceutical and R&D group, B Guillet focuses its activity on R&D in radiopharmaceuticals to patient care, is the co-author of more than 80 international Publications, co-inventor of 6 international Patents and responsible of a Master 2 degree dedicated to radiopharmaceutical.
Wendy Delbart (Université libre de Bruxelles) - Wendy Delbart is a PhD student at the Université libre de Bruxelles (ULB) and a research assistant in Nuclear Medicine Department at Institut Jules Bordet, Brussels, Belgium. She completed her Master in Biomedical Sciences in 2014 at the Université Catholique de Louvain (UCL). She is working part-time in clinical research, from the design of investigator-initiated trials to study conduct coordination and results analysis. Her PhD concerns the understanding of the radiobiology of Peptide Receptor Radionuclide Therapy (PRRT) in pre-clinical settings. She presented her work at national and international conferences. In 2020, she gave a lecture on radiobiology in the framework of annual Belgian Society of Nuclear Medicine (BELNUC) seminars. She won the 1^st prize of the "BELNUC Scientific award" in 2022 in giving a lecture in the field of radiobiology in the framework of the BELNUC congress. She is an active member of the European Association of Nuclear Medicine (EANM) and the BELNUC.
Bruno Vanderlinden (Université libre de Bruxelles) - Bruno Vanderlinden is a medical physicist expert since 2004. He works in the nuclear medicine department of Institut Jules Bordet. The department has developed a collaboration from the beginning with Prof Buvat to standardize PET/CT quantification. Hepatic radioembolization started in 2004 in our nuclear medicine department. Optimization of this radionuclide therapy based on dosimetry from FDG-PET/CT and MAA-SPECT/CT images has been undertaken from the beginning. Many other research works concerning dosimetry in the field of radiotheranostics have been and are being carried out in our department. The nuclear medicine department of the Institut Jules Bordet uses today in clinical routine many radiotracer couples dedicated to radiotheranostics: (89)Zr-rituximab/(90)Y-rituximab in 2010, (68)GA-DOTATATE/(177)Lu-DOTATATE and recently (68)GA-PSMA/(177)Lu-PSMA.
Stavros Spiliopoulos (National and Kapodistrian University of Athens) - Stavros Spiliopoulos is an Associate Professor of Interventional Radiology, at the 2^nd Department of Radiology, of the National and Kapodistrian University of Athens, “Attikon” University General Hospital, Greece and an Honorary Senior Lecturer in the Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Scotland, UK. He is the holder of the European Boards of Interventional Radiology (EBIR), a certified Endovascular Specialist (EBIR-ES), and a Fellow of the Cardiovascular and Interventional Society Europe (FCIRSE) Radiology. Dr. Spiliopoulos has published more than 180 peer-reviewed PubMed articles and 18 book chapters. He is an elected member of the Standards of Practice Committee of the Cardiovascular and Interventional Society of Europe (CIRSE), an elected member of the Board of the Greek Society of Interventional Radiology, an Associate Editor in two PubMed scientific journals, a member of the Editorial Board of 4 International peer review Journals He has received over 20 International Awards and Distinctions for his research in the field of Interventional Radiology. His main ongoing research interests include the endovascular management of peripheral arterial disease and dialysis vascular access, personalized vascular medicine, and loco-regional treatments of solid organ malignancies.

Schedule

15 September 2022 | 13:30 – 17:00 CET | VIRTUAL

13:30 - 13:45 CET	Welcome and introduction (Erwin WOFF, ULB)
13:45 - 14:45 CET	Session 1: Radiopharmaceuticals for targeted radionuclide therapy (Benjamin GUILLET, AMU)
14:45 - 15:45 CET	Session 2: Radiobiology (Wendy DELBART, ULB)
15:45 - 16:45 CET	Session 3: Medical physics dosimetry in nuclear medicine (Bruno VANDERLINDEN, ULB)
16:45 - 17:00 CET	Concluding remarks of Day 1

16 September 2022 | 13:30 – 16:10 CET | VIRTUAL

13:30 - 14:30 CET	Session 4: Radiotheranostics in clinics (Erwin WOFF, ULB)
14:30 - 15:30 CET	Session 5: Example of radioembolization (Stavros SPILIOPOULOS, NKUA)
15:30 - 16:00 CET	Session 6: Bottlenecks and pending questions from participants to all speakers (Benjamin GUILLET, Wendy DELBART, Bruno VANDERLINDEN, Erwin WOFF, Stavros SPILIOPOULOS)
16:00 - 16:10 CET	Concluding remarks of Day 2